Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity
B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was pre...
Saved in:
Published in | Rheumatology (Oxford, England) Vol. 55; no. 2; pp. 263 - 267 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.
Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.
The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.
These results suggest that decreased Breg cell levels may contribute to the development of SSc. |
---|---|
AbstractList | B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.
Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.
The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.
These results suggest that decreased Breg cell levels may contribute to the development of SSc. B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.OBJECTIVEB cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10 producing regulatory B (Breg) cells also play an important role in the negative immune response. We identified a human Breg cell subset that was predominantly found within the CD24(hi)CD27(+) B cell subpopulation. However, the role of Breg cells in SSc remains unknown. The aim of this study was to investigate the clinical association of Breg cells in SSc patients.Blood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.METHODSBlood IL-10 producing Breg cell levels were determined by FACS in 35 SSc patients and 30 healthy subjects. In a follow-up study, we analysed six individual dcSSc patients before and after treatment.The frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.RESULTSThe frequency of blood Breg cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). Similarly, the frequency of CD24(hi)CD27(+) B cells was significantly lower in SSc patients than in healthy controls (P < 0.0001). SSc patients with decreased Breg cell levels often had interstitial lung disease (P < 0.05). Furthermore, Breg cell levels correlated negatively with the titre of anti-topo I antibody (Ab) and anticentromere Ab in SSc patients. For a follow-up study, Breg cell levels in dcSSc patients after treatment were found to be significantly increased compared with those before treatment (P < 0.05), accompanied by decreased disease activity. Thus, Breg cell levels were inversely correlated with disease activity of SSc.These results suggest that decreased Breg cell levels may contribute to the development of SSc.CONCLUSIONThese results suggest that decreased Breg cell levels may contribute to the development of SSc. |
Author | Takehara, Kazuhiko Matsushita, Takashi Hasegawa, Minoru Fujimoto, Manabu Hamaguchi, Yasuhito |
Author_xml | – sequence: 1 givenname: Takashi surname: Matsushita fullname: Matsushita, Takashi – sequence: 2 givenname: Yasuhito surname: Hamaguchi fullname: Hamaguchi, Yasuhito – sequence: 3 givenname: Minoru surname: Hasegawa fullname: Hasegawa, Minoru – sequence: 4 givenname: Kazuhiko surname: Takehara fullname: Takehara, Kazuhiko – sequence: 5 givenname: Manabu surname: Fujimoto fullname: Fujimoto, Manabu |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26350483$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1OxCAUhYnR-P8EJoalm1EoHYa6818TEze6bijcjmhbRi4d00fwrWVm1BgXriCX79x7OWeHrHe-A0IOODvmrBAn4Rn6Vkff-Olw8gpzIfga2ea5zEZMiGz9557lW2QH8YUxNuZCbZKtTIoxy5XYJh-XYAJoBEsbmEOD1Nc0wLRvUucw0HNqoElV19GZjg66iPTdxWeKA0ZonaFoGggeHZ5SjeiNS5jvVpDuo9dddJW3A50Fb3uzfNSdpdbhYi7VqTR3cdgjG7VuEPa_zl3ydH31eHE7un-4ubs4ux-ZtHMcKcWE5JIXUHM-VnbCjeXKWFEAr2FSVJWEupK5rmUlikxYXWVc54XIVKWsycQuOVr1Tfu89YCxbB0uPqk78D2WfCKZknxcLNDDL7SvWrDlLLhWh6H8ti8BYgWY5AAGqH8QzspFSOXvkMpVSElV_FEZF5euxaBd86_2E_ZNomE |
CitedBy_id | crossref_primary_10_3390_biomedicines10092150 crossref_primary_10_1186_s13075_016_1213_9 crossref_primary_10_1093_postmj_qgae169 crossref_primary_10_1038_s41584_019_0184_z crossref_primary_10_1111_cei_13238 crossref_primary_10_1016_j_jid_2021_05_038 crossref_primary_10_3390_ph15080936 crossref_primary_10_2336_nishinihonhifu_83_397 crossref_primary_10_1111_imr_12941 crossref_primary_10_1371_journal_pone_0180726 crossref_primary_10_1016_j_rcreu_2023_09_001 crossref_primary_10_1111_jth_14427 crossref_primary_10_1016_j_autrev_2025_103782 crossref_primary_10_1136_ard_2021_221925 crossref_primary_10_1111_1346_8138_13994 crossref_primary_10_1016_j_autrev_2017_10_015 crossref_primary_10_1016_j_semarthrit_2018_10_007 crossref_primary_10_1016_j_jaut_2020_102526 crossref_primary_10_1038_srep27479 crossref_primary_10_1016_j_clim_2024_110195 crossref_primary_10_1093_rheumatology_keab257 crossref_primary_10_3389_fimmu_2022_1075813 crossref_primary_10_1111_cei_13501 crossref_primary_10_1016_j_jdermsci_2018_11_008 crossref_primary_10_1186_s13075_020_02153_8 crossref_primary_10_3390_ijms25010583 crossref_primary_10_3389_fphar_2022_826839 crossref_primary_10_1007_s00109_024_02424_w crossref_primary_10_3389_fimmu_2022_933468 crossref_primary_10_1016_j_clim_2017_04_013 crossref_primary_10_3389_fimmu_2017_00053 crossref_primary_10_3389_fimmu_2024_1328785 crossref_primary_10_1007_s00296_020_04658_6 crossref_primary_10_1007_s10067_021_05665_z crossref_primary_10_1016_j_revmed_2016_02_016 crossref_primary_10_1016_j_imlet_2019_08_004 crossref_primary_10_3389_fmed_2022_936182 crossref_primary_10_1186_s42358_024_00401_y crossref_primary_10_1186_s13075_020_02226_8 crossref_primary_10_1002_kjm2_12505 crossref_primary_10_1007_s00296_018_4076_3 crossref_primary_10_3389_fimmu_2022_999008 crossref_primary_10_3390_ph16081066 crossref_primary_10_1093_rheumatology_keac578 crossref_primary_10_1007_s10067_024_07086_0 crossref_primary_10_1016_j_jneuroim_2021_577520 crossref_primary_10_1016_j_imlet_2018_01_002 crossref_primary_10_1172_JCI85113 crossref_primary_10_1371_journal_pbio_3001513 crossref_primary_10_3389_fimmu_2018_00835 crossref_primary_10_3390_biology12020285 crossref_primary_10_3389_fimmu_2024_1373464 crossref_primary_10_1080_00207454_2023_2254922 crossref_primary_10_1111_1756_185X_13764 crossref_primary_10_1038_s41598_021_81588_8 crossref_primary_10_1111_bjd_15113 crossref_primary_10_3390_cells9010077 crossref_primary_10_1182_bloodadvances_2017011072 crossref_primary_10_1002_cia2_12059 crossref_primary_10_1016_j_autrev_2020_102730 crossref_primary_10_1007_s12026_018_8998_3 crossref_primary_10_1016_j_jcyt_2021_12_002 crossref_primary_10_1111_1346_8138_15117 crossref_primary_10_1093_rheumatology_keaa186 crossref_primary_10_1186_s42358_022_00279_8 crossref_primary_10_1016_j_rcreue_2024_05_002 crossref_primary_10_3389_fimmu_2022_941011 crossref_primary_10_1093_intimm_dxac048 crossref_primary_10_1126_sciadv_aas9944 crossref_primary_10_3389_fimmu_2022_921260 crossref_primary_10_3389_fimmu_2018_00622 crossref_primary_10_1093_stcltm_szad010 crossref_primary_10_3389_fimmu_2022_925741 crossref_primary_10_3389_fimmu_2021_773896 crossref_primary_10_1002_cia2_12288 crossref_primary_10_1016_j_jdermsci_2020_12_007 crossref_primary_10_3389_fimmu_2018_02241 crossref_primary_10_1016_j_jmb_2020_10_019 crossref_primary_10_4049_jimmunol_1801211 crossref_primary_10_1093_cei_uxac104 |
Cites_doi | 10.1016/j.immuni.2009.11.009 10.1182/blood-2010-07-294249 10.1002/art.1780230510 10.1002/art.20274 10.1182/blood-2012-11-465658 10.1007/BF00870304 10.2353/ajpath.2006.060205 10.1093/rheumatology/40.10.1135 10.1002/art.27233 10.1093/rheumatology/keu463 10.1002/art.22811 10.1038/sj.jid.5700919 10.1172/JCI36030 10.1002/art.34359 10.1002/art.1780251101 10.1056/NEJM197502132920706 10.1002/art.1780370313 10.1016/j.jdermsci.2010.08.010 |
ContentType | Journal Article |
Copyright | The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1093/rheumatology/kev331 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1462-0332 |
EndPage | 267 |
ExternalDocumentID | 26350483 10_1093_rheumatology_kev331 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYXX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGORE AGQPQ AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE CITATION COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c350t-880361619ef1158d71cd18cd39e1fe79bb6efb64af6b3923dab21a49328b8dc23 |
ISSN | 1462-0324 1462-0332 |
IngestDate | Fri Jul 11 11:14:50 EDT 2025 Mon Jul 21 05:51:09 EDT 2025 Thu Apr 24 22:53:00 EDT 2025 Tue Jul 01 01:36:34 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | IL-10 regulatory B cell systemic sclerosis |
Language | English |
License | The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c350t-880361619ef1158d71cd18cd39e1fe79bb6efb64af6b3923dab21a49328b8dc23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/rheumatology/article-pdf/55/2/263/17389189/kev331.pdf |
PMID | 26350483 |
PQID | 1760861592 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_1760861592 pubmed_primary_26350483 crossref_primary_10_1093_rheumatology_kev331 crossref_citationtrail_10_1093_rheumatology_kev331 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-02-00 2016-Feb 20160201 |
PublicationDateYYYYMMDD | 2016-02-01 |
PublicationDate_xml | – month: 02 year: 2016 text: 2016-02-00 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Rheumatology (Oxford, England) |
PublicationTitleAlternate | Rheumatology (Oxford) |
PublicationYear | 2016 |
References | 2016011223140161000_55.2.263.15 2016011223140161000_55.2.263.14 2016011223140161000_55.2.263.17 2016011223140161000_55.2.263.16 2016011223140161000_55.2.263.19 2016011223140161000_55.2.263.18 2016011223140161000_55.2.263.2 2016011223140161000_55.2.263.3 2016011223140161000_55.2.263.4 2016011223140161000_55.2.263.11 2016011223140161000_55.2.263.10 LeRoy (2016011223140161000_55.2.263.1) 1988; 15 2016011223140161000_55.2.263.13 2016011223140161000_55.2.263.12 2016011223140161000_55.2.263.9 2016011223140161000_55.2.263.5 2016011223140161000_55.2.263.6 2016011223140161000_55.2.263.7 2016011223140161000_55.2.263.8 |
References_xml | – ident: 2016011223140161000_55.2.263.8 doi: 10.1016/j.immuni.2009.11.009 – ident: 2016011223140161000_55.2.263.7 doi: 10.1182/blood-2010-07-294249 – ident: 2016011223140161000_55.2.263.10 doi: 10.1002/art.1780230510 – ident: 2016011223140161000_55.2.263.2 doi: 10.1002/art.20274 – ident: 2016011223140161000_55.2.263.6 doi: 10.1182/blood-2012-11-465658 – ident: 2016011223140161000_55.2.263.15 doi: 10.1007/BF00870304 – ident: 2016011223140161000_55.2.263.4 doi: 10.2353/ajpath.2006.060205 – ident: 2016011223140161000_55.2.263.14 doi: 10.1093/rheumatology/40.10.1135 – ident: 2016011223140161000_55.2.263.18 doi: 10.1002/art.27233 – ident: 2016011223140161000_55.2.263.5 doi: 10.1093/rheumatology/keu463 – ident: 2016011223140161000_55.2.263.9 doi: 10.1002/art.22811 – ident: 2016011223140161000_55.2.263.3 doi: 10.1038/sj.jid.5700919 – ident: 2016011223140161000_55.2.263.17 doi: 10.1172/JCI36030 – ident: 2016011223140161000_55.2.263.19 doi: 10.1002/art.34359 – ident: 2016011223140161000_55.2.263.11 doi: 10.1002/art.1780251101 – ident: 2016011223140161000_55.2.263.12 doi: 10.1056/NEJM197502132920706 – ident: 2016011223140161000_55.2.263.13 doi: 10.1002/art.1780370313 – volume: 15 start-page: 202 year: 1988 ident: 2016011223140161000_55.2.263.1 article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis publication-title: J Rheumatol – ident: 2016011223140161000_55.2.263.16 doi: 10.1016/j.jdermsci.2010.08.010 |
SSID | ssj0005138 |
Score | 2.4618392 |
Snippet | B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play an important role in the pathogenesis of SSc. IL-10... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 263 |
SubjectTerms | Adolescent Adult Aged Autoantibodies - biosynthesis Autoantibodies - immunology Autoimmunity B-Lymphocytes, Regulatory - immunology B-Lymphocytes, Regulatory - metabolism B-Lymphocytes, Regulatory - pathology Disease Progression Female Flow Cytometry Follow-Up Studies Humans Interleukin-10 - metabolism Lymphocyte Count Male Middle Aged Scleroderma, Systemic - immunology Scleroderma, Systemic - metabolism Scleroderma, Systemic - pathology Severity of Illness Index Young Adult |
Title | Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26350483 https://www.proquest.com/docview/1760861592 |
Volume | 55 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWGIiE2iDfDS0ZiV0LHcSaTsKM8VCENCzSVZhfZsd1GU5Jqkqilf8D38INcvxJXUARsooyTOEruGd97neNzEXpJuBKZXFAA75xGCYMYLqckjtScCPBAc8KYnodcfk4PDpNP6_l6MvkRsJb6jr8uL367ruR_rAptYFe9SvYfLDt0Cg2wD_aFLVgYtn9l4_cm5mshZjzR3B_Dytja4vL60_n-rp6Wt0RxK5_q1rJZ-eaq3G2hQ3CTleHFsdFSbslb3zXw4iveiG-ayCV6V1e8Fv7DjtHi0OUnwiD3y7HsIRC26k5azvTcM-hdyZBg-mHJurZvjysbxK7YRhd3CqbV2ZGu1mIcBWt7OK8ZD7byiJ0xS_6vm20_zkJspNahtmyRC7hq04SzG2QgRGvnZEfkJIUWSi8N2VbZ10EzDsdfO1r-4hesZtY2eHz4CVZ1y8UCrJx-NWDRGj1abX90kwN50R-6hq7HkJuYFebrgFdEaOblrXK6F95zz95RC1C7Pi5HQ1ekOCbUWd1Gt1yOgt9awN1BE1nfRTeWjoVxD30fcIct7nCj8Ig7vI8N7nBVY487rAGFPe7wgLs3OECdPSlEHR5RhwE32KEOe9TdR4cfP6zeHUSupEdUwgN3EXgLmkKSkUsFqUgmFqQUJCsFzSVRcpFznkrF04SplEPkTgXjMWEJJBkZz0QZ0wdop25q-QhhpSB1nnFI9xOVaA0iVSZlRmZMEUYXMpui2L_aonR697rsyklheRe0CE1TWNNM0avholMr9_Ln0194mxUwLOuXy2rZ9G1BFuksg2whj6fooTXm0KE3_uMrjzxBN8c_w1O00217-QyC344_N2D7CeeQvgc |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Decreased+levels+of+regulatory+B+cells+in+patients+with+systemic+sclerosis%3A+association+with+autoantibody+production+and+disease+activity&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Matsushita%2C+Takashi&rft.au=Hamaguchi%2C+Yasuhito&rft.au=Hasegawa%2C+Minoru&rft.au=Takehara%2C+Kazuhiko&rft.date=2016-02-01&rft.eissn=1462-0332&rft.volume=55&rft.issue=2&rft.spage=263&rft_id=info:doi/10.1093%2Frheumatology%2Fkev331&rft_id=info%3Apmid%2F26350483&rft.externalDocID=26350483 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |